Ataluren: First global approval

Drugs

Volumn 74, Issue 14, 2014, Pages 1709-1714

  Ryan, Nicola J ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; LIPID; MESSENGER RNA; MOLECULAR LIBRARY; OXADIAZOLE DERIVATIVE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; CYSTIC FIBROSIS; DIZZINESS; DRUG APPROVAL; DRUG MECHANISM; DRUG STRUCTURE; DUCHENNE MUSCULAR DYSTROPHY; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONSENSE MUTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREMATURE STOP CODON; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STOP CODON; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; CONFORMATION; GENETICS; MOLECULAR LIBRARY; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; THERAPEUTIC USE;

ANIMALS; DRUG APPROVAL; HUMANS; MOLECULAR CONFORMATION; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; OXADIAZOLES; SMALL MOLECULE LIBRARIES;

EID: 84910627623     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0287-4     Document Type: Article

References (34)

1. Kellermayer R. Translational readthrough induction of pathogenic nonsense mutations. Eur J Met Genet. 2006;49(6):445-50.
2. Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell. 2001;107(4):411-4.
3. PTC Therapeutics Inc. PTC therapeutics receives orphan drug designation for PTC124 for the treatment of cystic fibrosis [media release]. 2004. http://www.ptcbio.com.
4. PTC Therapeutics Inc. European Medicines Agency (EMEA) Grants PTC therapeutics orphan drug designation for PTC124 for the treatment of duchenne muscular dystrophy and cystic fibrosis [media release]. 2005. http://www.ptcbio.com.
5. PTC Therapeutics Inc. FDA's office of orphan products development awards PTC therapeutics a grant to support clinical development of PTC124 for the treatment of nonsense-mutation-mediated cystic fibrosis [media release]. 2005. http://www.ptcbio.com.
6. PTC Therapeutics Inc. PTC therapeutics receives orphan drug designation for PTC124 for the treatment of duchenne muscular dystrophy [media release]. 2005. http://www.ptcbio.com.
7. PTC Therapeutics Inc. FDA awards PTC therapeutics orphan products development grant for the development of PTC124 in Duchenne muscular dystrophy [media release]. 2006. http://www.ptcbio.com.
8. PTC Therapeutics Inc. PTC therapeutics announces 25 million award from cystic fibrosis foundation therapeutics for development of PTC124 [media release]. 2008. http://www.ptcbio.com.
9. PTC Therapeutics Inc. PTC therapeutics announces european medicines agency validation of marketing authorization application for ataluren in Duchenne muscular dystrophy [media release]. 2012. http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=725244.
10. PTC Therapeutics Inc. PTC therapeutics receives positive opinion from CHMP for Translarna™ (ataluren) [media release]. 2014. http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=850246.
11. PTC Therapeutics Inc. PTC therapeutics provides update on CHMP opinion for conditional approval of ataluren for nonsense mutation Duchenne muscular dystrophy [media release]. 2014. http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=820977.
12. PTC Therapeutics. PTC therapeutics receives conditional approval in the European Union for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy [media release]. 2014. http://ir.ptcbio.com/ReleaseDetail.cfm?ReleaseID=863914.
13. European Commission. Commission Immplemeting Decision of 31.7.14 granting a conditional marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Translarna - ataluren", an orphan medicinal product for human use [media release]. 2014. http://ec.europa.eu/health/documents/community-register/2014/20140731129187/dec-129187-en.pdf.
14. PTC Therapeutics. PTC therapeutics reports first quarter financial results and provides corporate update [media release]. 2014. http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=845413.
15. Genzyme Corporation, PTC Therapeutics Inc. Genzyme corporation and PTC therapeutics announce collaboration on small molecule for genetic diseases [media release]. 2008. http://www.genzyme.com.
16. Sanofi-Aventis. Sanofi-Aventis completes acquisition of genzyme corporation [media release]. 2011. http://www.sanofi-aventis.com.
17. PTC Therapeutics Inc, Genzyme. PTC therapeutics and genzyme announce restructuring of collaboration [media release]. 2011. http://www.ptcbio.com.
18. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447(7140):87-91.
19. Li M, Andersson-Lendahl M, Sejersen T, et al. Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment. FASEB J. 2014;28(4):1593-9.
20. Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS ONE. 2013;. doi: 10.1371/journal.pone.0081302.
21. Du M, Liu X, Welch E, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA. 2008;105(6):2064-9.
22. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372(9640):719-27.
23. Sermet-Gaudelus I, De Boeck K, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010;182(10):1262-72.
24. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J. 2011;38(1):59-69.
25. Auld DS, Thorne N, Maguire WF, et al. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA. 2009;106(9):3585-90.
26. McElroy SP, Nomura T, Torrie LS, et al. A lack of premature termination codon read-through efficacy of PTC124 (ataluren) in a diverse array of reporter assays. PLoS Biol. 2013;11(6):e1001593.
27. Goldmann T, Overlack N, Wolfrum U, et al. PTC124-mediated translational readthrough of a nonsense mutation causing usher syndrome type 1C. Hum Gene Ther. 2011;22(5):537-47.
28. Sarkar C, Zhang Z, Mukherjee AB. Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Mol Genet Metab. 2011;104(3):338-45.
29. Tan L, Narayan SB, Chen J, et al. PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis. 2011;34(2):443-7.
30. Melhem M, Van Wart S, Rubino C, et al. Population pharmacokinetic (PK) analyses to bridge ataluren disposition between healthy adults and patients with nonsense mutation duchenne-becker muscular dystrophy (nmDBMD) [abstract no. W-023]. J Pharmacokinet Pharmacodyn. 2013;40(suppl. 1):S121-3.
31. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007;47(4):430-44.
32. Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014. doi: 10.1002/mus.24332 (Epub ahead of print).
33. Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2(7):539-47.
34. PTC Therapeutics Limited. Translarna (ataluren) European Summary of Product Characteristics. 2014. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm408475.htm. Accessed 15 Aug 2014.